Eisai, Bristol Myers Squibb enter collaboration for Eisai’s MORAb-202 antibody-drug conjugate
The companies are planning to move into the registrational stage of development for this asset as early as next year
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Bristol-Myers Squibb Company
Bristol-Myers Squibb Completes Acquisition of Celgene
Upon completion of the acquisition, pursuant to the terms of the merger agreement, Celgene became a wholly owned subsidiary of…